Drug name
Last update: Oct 2026GS-0415
Developer(s)
Drug information
Not provided
GS-0415 (investigational)
Not applicable (investigational; no brand name assigned)
Biotherapeutic
Not disclosed
GS-0415 is an investigational agent from Gilead Sciences for the treatment of HIV-1. Its structure and mechanism of action have not been disclosed. A first-in-human phase 1 study (NCT07719491), recruiting in the United States since July 2026, evaluates single and multiple ascending subcutaneous or intravenous doses in virologically suppressed adults on stable ART.
Not approved. Phase 1 (recruiting).
Unknown
Therapeutic area(s)
- HIV
- Treatment
Administration route
Subcutaneous, Intravenous
Associated long-acting platforms
Monoclonal antibodies and antibody drug conjugates
Use of drug
- To be determined
- Other/Variable/Unknown : To be determined based on clinical development
Dosage
Not disclosed
Not disclosed
Not established. Phase 1 (NCT07719491): single ascending doses SC or IV versus placebo; multiple ascending doses SC/IV (five administrations up to Day 57) versus placebo.
Not provided
Not provided
Related entries
Not provided
Additional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Detailed manufacturing information is not currently available for this compound.
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL